GHRH(1-44) (human), somatorelin / Studies

Natural peptide · 44 amino acids · 5,039.7 Da

GHRH(1-44) (human), somatorelin studies and research data

PepBank has no study results for GHRH(1-44) (human), somatorelin yet. Data as of 2026-10-30.

Searches 0 results and 0 papers. Newer studies from Europe PMC

Results in people

0% of 0 results

Results in animals

0% of 0 results

Results in lab cells

0% of 0 results

From computer models

0% of 0 results

The molecule

GHRH(1-44) (human), somatorelin identity

Identifiers, parent molecule, targets and development stage, from curated data.

Growth hormone-releasing hormone, also called growth hormone-releasing factor or somatoliberin, is the mature 44-residue peptide cut from the human GHRH precursor (UniProt P01286) and carrying a C-terminal leucinamide. It is released by the hypothalamus and acts on the GHRH receptor on pituitary somatotroph cells to drive growth hormone synthesis and pulsatile release. The INN for the synthetic peptide is somatorelin, and it has been used as a diagnostic agent (WHO ATC V04CD05). This record is a reference parent for sermorelin, tesamorelin, CJC-1295 and Mod GRF (1-29).

Kind: Natural peptide · 44 residues
Identifiers: UniProtP01286 (opens in a new tab)ChEMBLCHEMBL2108862 (opens in a new tab)PubChem CID16132353 (opens in a new tab)UNII4UR7N9Z9MM (opens in a new tab)DrugBankDB12656 (opens in a new tab)CAS83930-13-6PDB7CZ5 (opens in a new tab)7V9M (opens in a new tab)KEGGD08523 (opens in a new tab)D03326 (opens in a new tab)
Development: No known clinical developmentChEMBL lists max_phase 4 for CHEMBL2108862 (SOMATORELIN), but no FDA or EMA approval was found in this check, so the phase claim is not confirmed and is recorded as unknown here. GHRH is widely used as a research and diagnostic stimulus; 38 ClinicalTrials.gov records name it as an intervention (query.intr=EXPANSION[Term]"growth hormone-releasing hormone" OR EXPANSION[Term]GHRH OR EXPANSION[Term]somatorelin). Source (opens in a new tab)

Targets

Molecular targets with action and evidence source
Target	Action	Evidence
Growth hormone-releasing hormone receptorGHRHRQ02643 (opens in a new tab)	Agonist	primary literatureSource (opens in a new tab)

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

44 amino acids · 1 modification

H-

YADAIFTNSY

RKVLGQLSAR

KLLQDIMSRQ

QGESNQERGA

RARL

Properties

From identity sources

Formula: C₂₁₅H₃₅₈N₇₂O₆₆S
Molecular weight: 5,039.7 g/mol
Monoisotopic mass: 5,036.6591 Da

UniProt P01286(opens in a new tab)retrieved 2026-10-09
GSRS UNII 4UR7N9Z9MM(opens in a new tab)retrieved 2026-10-09
PubChem CID 16132353(opens in a new tab)retrieved 2026-10-09

Calculated from the sequence

pKa set

Average mass: 5,039.71 Da; Sum of ExPASy residue masses + water + C-amide · ExPASy Compute pI/Mw; FindMod
Monoisotopic mass: 5,036.6591 Da; Sum of ExPASy residue masses + water + C-amide · ExPASy FindMod
Isoelectric point (pI): 11.43; pH of zero net charge, EMBOSS pKa set · EMBOSS iep, Epk.dat
Net charge at pH 7.4: 4.94; Henderson-Hasselbalch, EMBOSS pKa set · EMBOSS iep, Epk.dat
GRAVY (hydropathy): −0.798; Mean Kyte-Doolittle hydropathy · Kyte and Doolittle 1982; Negative: hydrophilic on average.
Extinction coefficient, 280 nm (Cys reduced): 2,980 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam); No Trp: ExPASy reports more than 10 % error without Trp.
Instability index: 38.48; Dipeptide instability weights (DIWV) · Guruprasad et al. 1990; 40 or below: classed as stable (ExPASy).
Aliphatic index: 80.0; Mole % A + 2.9 V + 3.9 (I + L) · Ikai 1980
Boman index: 3.03 kcal/mol; Mean solubility value (negated) · Boman 2003; Above 2.48: high protein-binding potential (Boman).
Hydrophobic moment (μH): 0.612; Eisenberg scale, 100° per residue, best 11-residue window · Eisenberg et al. 1982, 1984
pI with each pKa set: EMBOSS 11.43Bjellqvist (ExPASy) 10.90IPC peptide 11.34IPC protein 11.04

Defined and validated for proteins; use with care for short peptides.
Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

pI 11.43 · Net charge at pH 7.4: 4.94

Point or use arrow keys

Henderson-Hasselbalch, EMBOSS pKa set, C-amide. Calculated, not measured.

Show as table

pH	Net charge
0	9.00
1	9.00
2	8.96
3	8.63
4	7.00
5	5.37
6	5.04
7	4.98
8	4.78
9	4.10
10	2.86
11	0.82
12	−1.30
13	−4.54
14	−5.81

Composition

Hydrophobic32% (14)A I L M V
Aromatic7% (3)F Y
Positive18% (8)K R
Negative9% (4)D E
Polar27% (12)N Q S T
Special7% (3)G

44 residues. Each residue counts in one class; F and W count as aromatic.

A Ala5 · 11%

I Ile2 · 5%

L Leu5 · 11%

M Met1 · 2%

V Val1 · 2%

F Phe1 · 2%

W Trp0 · 0%

Y Tyr2 · 5%

H His0 · 0%

K Lys2 · 5%

R Arg6 · 14%

D Asp2 · 5%

E Glu2 · 5%

N Asn2 · 5%

Q Gln5 · 11%

S Ser4 · 9%

T Thr1 · 2%

C Cys0 · 0%

G Gly3 · 7%

P Pro0 · 0%

3D structure

ExperimentalPDB 7CZ5

Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from RCSB PDB.

2D structure

GHRH(1-44) (human), somatorelin has 44 residues. A full-atom drawing is hard to read at this size; the sequence view is the reference.

SMILES fromPubChem CID 16132353(opens in a new tab)

CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(=O)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC3=CC=C(C=C3)O)N

Helical wheel

An ideal alpha-helix projection. It shows where the hydrophobic residues fall if the peptide folds as a helix. It does not show that it does.

μH, residues shown: 0.044
μH, best 11-residue window: 0.612
Arrow direction: 52°
Residues: 44 · 3 rings of 18

HydrophilicHydrophobic

Eisenberg consensus (normalized) scale · + K, R · − D, E

Assumes an ideal α-helix: 100° per residue, 3.6 residues per turn. The arrow is the mean hydrophobic moment (Eisenberg et al. 1984) and points at the hydrophobic face.

Show as table

Position	Residue	Angle	Eisenberg consensus (normalized)
1	Y	0°	0.26
2	A	100°	0.62
3	D	200°	-0.90
4	A	300°	0.62
5	I	40°	1.38
6	F	140°	1.19
7	T	240°	-0.05
8	N	340°	-0.78
9	S	80°	-0.18
10	Y	180°	0.26
11	R	280°	-2.53
12	K	20°	-1.50
13	V	120°	1.08
14	L	220°	1.06
15	G	320°	0.48
16	Q	60°	-0.85
17	L	160°	1.06
18	S	260°	-0.18
19	A	0°	0.62
20	R	100°	-2.53
21	K	200°	-1.50
22	L	300°	1.06
23	L	40°	1.06
24	Q	140°	-0.85
25	D	240°	-0.90
26	I	340°	1.38
27	M	80°	0.64
28	S	180°	-0.18
29	R	280°	-2.53
30	Q	20°	-0.85
31	Q	120°	-0.85
32	G	220°	0.48
33	E	320°	-0.74
34	S	60°	-0.18
35	N	160°	-0.78
36	Q	260°	-0.85
37	E	0°	-0.74
38	R	100°	-2.53
39	G	200°	0.48
40	A	300°	0.62
41	R	40°	-2.53
42	A	140°	0.62
43	R	240°	-2.53
44	L	340°	1.06

Results by area

GHRH(1-44) (human), somatorelin results by year and outcome

Counts are exact and come from studies that gave the peptide.

Studies by year

No study has results about GHRH(1-44) (human), somatorelin yet.

No study with a publication year is linked to this peptide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

No study of GHRH(1-44) (human), somatorelin has results in PepBank yet.

Trials and papers

GHRH(1-44) (human), somatorelin trials

Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.

StatusPhase

0 trials match. Highest phase first. Data from ClinicalTrials.gov.

No trial matches these filters.

Papers

Studies on this peptide. Some have results. The others have none yet.

Sort

Design

0 studies match. Retracted studies are left out.

No study matches these filters.

Newer studies

PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.

GHRH(1-44) (human), somatorelin studies: 0 papers with results

No paper with results is linked to this peptide.

Status and safety

Regulatory and safety

Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.

Regulatory status by jurisdiction, with date and source
Jurisdiction	Body	Status	As of	Source
US	FDA	No Drugs@FDA application was found for somatorelin (openFDA drugsfda searches on 2026-10-09 returned no matches). Four FDA orphan designations are linked from the GSRS record, all with status Designated and none approved: growth hormone releasing factor for paediatric growth failure (1989-08-07, Valeant Pharmaceuticals North America); somatorelin as a diagnostic measure of pituitary capacity to release growth hormone (1989-08-08, Ferring Laboratories); GHRH 1-44 human amide for growth hormone deficiency (2016-02-23, Hollenbeck Pharmaceuticals); GHRH 1-44 human amide with arginine for diagnosis of growth hormone deficiency (2022-03-07, Hollenbeck Pharmaceuticals).	9 Oct 2026	accessdata.fda.gov (opens in a new tab)
EU	EMA	No match for somatorelin or GHRH(1-44) in the EMA medicines data file or the EMA orphan designation data file, both downloaded 2026-10-09 (medicines file timestamp 2026-10-09T06:23:44Z, 2,746 records; orphan designations file timestamp 2026-10-09T06:32:20Z, 3,310 records). The orphan file lists EU/3/11/947 (withdrawn) for a recombinant fusion protein of modified GHRH, which is a different substance.	9 Oct 2026	ema.europa.eu (opens in a new tab)
Sport	WADA	Banned in sport (WADA S2.2.4) S2.2.4 prohibits growth hormone-releasing hormone (GHRH) and its analogues.	2026 List	wada-ama.org (opens in a new tab)
Japan	Note	KEGG DRUG lists D03326 'Somatorelin acetate (JAN); GRF (TN)'. A Japanese Accepted Name with a trade name suggests a Japanese product; the approval was not verified against a PMDA source, so this is recorded as a lead, not as a confirmed approval.	9 Oct 2026	rest.kegg.jp (opens in a new tab)
WHO ATC	Note	ATC code V04CD05 (diagnostic agents, tests for pituitary function), from the GSRS code list.	9 Oct 2026	gsrs.ncats.nih.gov (opens in a new tab)

Safety outcomes

Reported effects from study results.

No study results yet

No safety results yet. That does not mean the peptide is safe.

Doses studied

The doses that these studies used. They are not recommendations.

No dose was reported in the study results.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Data

Data and API

Data version, change history and code for this peptide.

Data version 30856030 Oct 2026

Peptide

Peptide id: PEP-000049
Peptide version: 8
Peptide hash: 0782a433b3f2b077…
Data version: 308560

Latest changes

27 Oct 2026UpdatedData version 256689
22 Oct 2026UpdatedData version 254521
21 Oct 2026UpdatedData version 213617
14 Oct 2026UpdatedData version 194691
13 Oct 2026UpdatedData version 173540
12 Oct 2026UpdatedData version 165115

For developers

curl -s https://pepbank.io/v1/briefs/ghrh

Evidence summary for GHRH(1-44) (human), somatorelin: counts by class, key results with sources, notices, data version.

Peptide as JSON Evidence summary as JSON

GHRH(1-44) (human), somatorelin studies and research data

GHRH(1-44) (human), somatorelin identity

Targets

Sequence and structure

Sequence

Properties

Net charge by pH

Composition

3D structure

2D structure

Helical wheel

GHRH(1-44) (human), somatorelin results by year and outcome

What the studies measured

GHRH(1-44) (human), somatorelin trials

Papers

Newer studies

GHRH(1-44) (human), somatorelin studies: 0 papers with results

Regulatory and safety

Doses studied

Data and API

Peptide

Latest changes

For developers

Related peptides

GHRH(1-44) (human), somatorelin results by year and outcome

GHRH(1-44) (human), somatorelin trials

Papers

Regulatory and safety

Doses studied

Data and API

Peptide

Latest changes

For developers